About Dr. Allison
Dr. James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Dr. Allison is one of the world’s most renowned scientists. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
In the News
National Academy of Sciences awards Kovalenko medal to immunotherapy pioneer Allison
MD Anderson’s Jim Allison named one of TIME’s 100 most influential people
Celebrating immunotherapy’s ‘Most Influential’ pioneer
Checkpoint inhibitors fire up different types of T cells to attack tumors
The game changer
Chief Scientific Advisor ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX
Vivian L. Smith Distinguished Chair in Immunology, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Chair, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX
Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX
|1973||The University of Texas at Austin, Austin, TX, USA, PHD, Biological Sciences|
|1969||The University of Texas at Austin, Austin, TX, USA, BS, Microbiology|
|1974-1977||Postdoctoral Fellow, Department of Molecular Immunology, Scripps Clinic and Research Foundation, La Jolla, CA|
Professor, Weill Cornell Medicine, New York, NY, 2004 - 2012
Adjunct Professor, Department of Medicine, Division of Division of Rheumatology, University of California, San Francisco School of Medicine, San Francisco, CA, 1997 - 2004
Professor, Department of Molecular and Cell Biology, Division of Division of Immunology, University of California, Berkeley, Berkeley, CA, 1985 - 2004
Associate Biochemist and Associate Professor, Department of Biochemistry, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX, 1983 - 1984
Visiting Scholar, Department of Pathology, Stanford University School of Medicine, Stanford, CA, 1983 - 1984
Adjunct Assistant Professor, Department of Zoology, The University of Texas at Austin, Austin, TX, 1979 - 1984
Assistant Biochemist and Assistant Professor, Department of Biochemistry, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX, 1977 - 1983
Director, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2006 - 2012
Co-Chair, Department of Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY, 2004 - 2012
Co-Chair, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, 1998 - 2000
Division Head, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, 1989 - 1997
Division Head ad interim, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, 1987 - 1989
Director, Department of Cancer Research Laboratory, University of California, Berkeley, Berkeley, CA, 1985 - 2004
Attending Immunologist, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2004 - 2012
Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, 1997 - 2012
Special Associate Member of the Graduate Faculty, The University of Texas at Austin, Austin, TX, 1980 - 1984
Institutional Committee Activities
Member, Advisory Committee, 2012 - Present
Member, Institutional Research Executive Committee, 2012 - Present
Member, Strategic Faculty Hiring (SFH) Committee, 2012 - Present
Member, Promotion and Tenure Committee, 2012 - Present
David H. Koch Chair in Immunologic Studies, Department of Immunology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, 2004 - 2012
|2017||Wolf Prize for Medicine, Wolf Foundation|
|2017||Sjoberg Prize for Cancer Research, Royal Swedish Academy of Sciences (RSAS)|
|2016||Honorary Doctorate of Science, Rockefeller University|
|2016||Honorary Doctorate, Icahn School of Medicine at Mount Sinai|
|2016||Honorary Award, The Hope Funds for Cancer Research|
|2016||Distinguished Scientist Award, Association of American Cancer Institutes (AACI)|
|2016||Fudan Zhongzhi Science Award, Fudan University and Zhongzhi Enterprise Group|
|2015||Science of Oncology Award, American Society of Clinical Oncology (ASCO)|
|2015||The Benvenuto Memorial Award, The University of Texas MD Anderson Cancer Center, Experimental Therapeutics|
|2015||President’s Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center, Experimental Therapeutics|
|2015||Harvey Prize in Human Health, Technion, Israel Institute of Technology|
|2015||The Passano Award, The Passano Foundation, Inc|
|2015||Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research, AACR|
|2015||Medal of Honor for Basic Research, American Cancer Society (ACS)|
|2015||Lasker-DeBakey Clinical Medical Research Award, The Lasker Foundation|
|2015||Lifetime Achievement in Melanoma Research Award, Society for Melanoma Research|
|2015||Paul Ehrlich and Ludwig Darmstaedter Prize, Paul Ehrlich Foundation|
|2014||Breakthrough Prize in Life Sciences, Breakthrough Prize Foundation|
|2014||Szent-Gyorgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR)|
|2014||President's Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center|
|2014||Canada Gairdner International Award, The Gairdner Foundation|
|2014||Tang Prize for Biopharmaceutical Science, Tang Prize Foundation|
|2014||Giants of Cancer Care Award in Scientific Advances, Intellisphere Oncology Specialty Group|
|2014||Distinguished Alumnus Award, Texas Exes|
|2014||Meira and Shaul G. Massry Prize, The Meira and Shaul G. Massry Foundation|
|2014||Prize for Scientific Excellence in Medicine, American-Italian Cancer Foundation|
|2014||Louisa Gross Horwitz Prize, Columbia University|
|2014||Distinguished Research in the Biomedical Sciences Award, Association of American Medical Colleges (AAMC)|
|2014||G.H.A. Clowes Memorial Award, American Association for Cancer Research (AACR)|
|2014||Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Science, The University of Texas MD Anderson Cancer Center|
|2013||Lloyd J. Old Award in Cancer Immunology, American Association for Cancer Research (AACR)-Cancer Research Institute (CRI)|
|2013||Novartis Award for Clinical Immunology, Novartis|
|2013||Innovations Award in BioScience, Economist|
|2012||Lifetime Achievement Award, Molecular Targeted Therapy Group|
|2012||Heath Memorial Award, The University of Texas MD Anderson Cancer Center|
|2011||Lifetime Achievement Award, American Association of Immunologists (AAI)|
|2011||Roche Award, Cancer Immunology and Immunotherapy|
|2011||Breakthrough Achievements in Translational Cancer Research, American Skin Association|
|2011||Jacob Heskel Gabbay Award in Biotechnology and Medicine, Brandeis University|
|2011||Advancement of Cancer Research Award, Gilda's Club|
|2010||Richard V. Smalley, MD, Memorial Lectureship Award, International Society for Biological Therapy of Cancer|
|2008||C. Chester Stock Award for Distinguished Achievement in Biomedical Research, Memorial Sloan-Kettering Cancer Center (MSKCC)|
|2008||Dana Foundation Award in Human Immunology Research, American Association of Immunologists (AAI)|
|2005||William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute (CRI)|
|2002||Outstanding Alumnus Award, The University of Texas at Austin Graduate School|
|2002||CaP CURE Research Award, CaP CURE|
|2001||Centeon Award for Innovative Breakthroughs in Immunology, Aventis Behring GmbH|
|1998||CaP CURE Research Award, CaP CURE|
|1986||Merit Award, National Institutes of Health (NIH)|
- Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. PMID: 28803728.
- Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 2014. e-Pub 2014. PMID: 24687957.
- Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6(226):226ra32, 2014. PMID: 24598590.
- Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107(9):4275-80, 2010. e-Pub 2010. PMID: 20160101.
- Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206(8):1717-25, 2009. e-Pub 2009. PMID: 19581407.
- Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res 68(3):889-92, 2008. PMID: 18245491.
- Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935-45, 2006. e-Pub 2006. PMID: 16778987.
- van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355-66, 1999. PMID: 10430624.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-6, 1996. PMID: 8596936.
- Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182(2):459-65, 1995. PMID: 7543139.
- Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370):607-9, 1992. PMID: 1313950.
- McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 34(3):739-46, 1983. PMID: 6194888.
- Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 270(5238):932-3, 1995. PMID: 7481795.
|Title:||Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy|
|Funding Source:||American Association for Cancer Research (AACR)|
|Title:||Recruitment of Established Investigators|
|Funding Source:||Cancer Prevention & Research Institute of Texas (CPRIT)|
|Title:||Cancer Center Support (CORE) Grant - Immunology CCSG|